Patents by Inventor Norica Nichita

Norica Nichita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8957106
    Abstract: A proliferation of cells can be reduced by contacting the cells with a compound having formula (I) where R and R? are each alkyl groups, R? is hydrogen or an alkyl group and X3, X4 and X5 are each independently selected from the group consisting of hydrogen, benzyl, t-butyldimethylsiloxy radical and triphenylmethyl. Accordingly, compounds of formula (I) can be used for treatment of tumors including melanoma. Also a secretion of a matrix metalloproteinase (MMP) enzyme by cells can be reduced by contacting the cells with the compound having formula (I). Accordingly, compounds of formula (I) can be used for treatment physiological conditions associated with an elevated MMP level, such as tumors.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: February 17, 2015
    Assignee: The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Raymond Dwek, Wanda Buzgariu, Anca Hirtopeanu, Robert Moriarty, Gabriela Negroiu, Norica Nichita, Livia Zdrentu, Nicole Zitzmann
  • Publication number: 20110182982
    Abstract: One can treat a viral infection such as hepatitis B (HBV), hepatitis C(HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N-butyl deoxynojirimycin (NB-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of NB-DNJ directly into the ER can be also applied for the treatment of other viruses, for which NB-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV).
    Type: Application
    Filed: March 23, 2011
    Publication date: July 28, 2011
    Inventors: Raymond A. Dwek, Norica Nichita-Branza, Stefana Petrescu, Stephanie Pollock, Pauline Rudd, Christopher Scanlan, Nicole Zitzmann
  • Publication number: 20080280972
    Abstract: A proliferation of cells can be reduced by contacting the cells with a compound having formula (I) where R and R? are each alkyl groups, R? is hydrogen or an alkyl group and X3, X4 and X5 are each independently selected from the group consisting of hydrogen, benzyl, t-butyldimethylsiloxy radical and triphenylmethyl. Accordingly, compounds of formula (I) can be used for treatment of tumors including melanoma. Also a secretion of a matrix metalloproteinase (MMP) enzyme by cells can be reduced by contacting the cells with the compound having formula (I). Accordingly, compounds of formula (I) can be used for treatment physiological conditions associated with an elevated MMP level, such as tumors.
    Type: Application
    Filed: April 18, 2008
    Publication date: November 13, 2008
    Inventors: Raymond Dwek, Wanda Buzgariu, Anca Hirtopeanu, Robert Moriarty, Gabriela Negroiu, Norica Nichita, Livia Zdrentu, Nicole Zitzmann
  • Publication number: 20080138351
    Abstract: One can treat a viral infection such as hepatitis B (HBV), hepatitis C (HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N-butyl deoxynojirimycin (NB-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of NB-DNJ directly into the ER can be also applied for the treatment of other viruses, for which NB-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV).
    Type: Application
    Filed: August 2, 2007
    Publication date: June 12, 2008
    Inventors: Raymond A. Dwek, Norica Nichita-Branza, Stefana Petrescu, Stephanie Pollock, Pauline Rudd, Christopher Scanlan, Nicole Zitzmann
  • Publication number: 20030124160
    Abstract: The use of pH-sensitive liposomes enhances the delivery of drugs that target the endoplasmic reticulum, reducing the required dosage compared to direct administration of the drug without such liposomes. In particular, antiviral compounds such as N-butyldeoxynojirnmycin can be used in lower amounts when administered in a pH-sensitive liposome.
    Type: Application
    Filed: October 11, 2002
    Publication date: July 3, 2003
    Inventors: Stefana M. Petrescu, Gertrude E. Costin, Mihaela Trif, Norica Nichita, Raymond A. Dwek